secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001437749-25-023646
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports neflamapimod 54% risk reduction on CDR-SB at Week 32 in DLB trial
--------------------------------------------------------------------------------

- At Week 32, neflamapimod showed 54% risk reduction in >=1.5-point CDR-SB worsening vs control (p=0.0037); 64% in ptau181<2.2 patients (p=0.0001).
- Significant reduction in plasma GFAP biomarker: mean change -18.4 pg/mL (p<0.0001) for New Capsules over 32 weeks.
- Plans to initiate Phase 3 trial and meet with FDA in Q4 2025 to align on trial design.
- New Capsules achieved target plasma exposures; Old Capsules did not; similar safety profiles.
- Trial funded by $21.3M NIH/NIA grant; 43 sites across US, UK, Netherlands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925023646/0001437749-25-023646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925023646/crvo20250728_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-023646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer